Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma

Exclusion Criteria

• •Contraindication of lenvatinib and excipient
• •1. Cardiovascular:
• •* Rhythmic or ischemic recent or uncontrolled cardiac disease: Pacemakers or patients who have a history of cardiac arrhythmias or irregular heartbeats (in case of electroporation procedure)
• •* Congestive heart failure New York Heart Association (NYHA) ≥ class 2
• •* Unstable angina or myocardial infarction within the past 6 months before enrolment
• •* Uncontrolled arterial hypertension (systolic ≥ 140 mmHg, diastolic ≥ 90 mmHg)
• •2. Ongoing ascites: Refractory ascites according to EASL guidelines definition (ascites that cannot be mobilized or the early recurrence of which cannot be prevented because of a lack of response to sodium restriction and diuretic treatment)
• •3. Coagulopathy
• •4. Ongoing infection \> Grade 2 according to NCI-current CTCAE . Hepatitis B is allowed if no active replication is present (below 100 IU/mL). Hepatitis C is allowed if no antiviral treatment is ongoing
• •Known hypersensitivity to the study drug or excipients in the formulation
• •Decompensated cirrhosis (Child-Pugh \> A6)
• •Prior systemic therapy with oral TKI and/or immunotherapy
• •Past or concurrent history of neoplasm other than HCC, except for in situ carcinoma of the cervix uteri and/or non-melanoma skin cancer and superficial bladder tumours. Any cancer curatively treated \> 3 years prior to study entry is permitted
• •Recent digestive bleeding associated with portal hypertension (whithin the 3 months prior to inclusion in the study)
• •Advanced or Metastatic HCC (BCLC C)
• •Persistent proteinuria of NCI-current CTCAE ≥ Grade ≥ Grade 3
• •Project of living donor
• •Pregnant or lactating woman
• •Curator or guardianship or patient placed under judicial protection
• •Participation in other interventional research during the study.
• •History within the past 3 months before enrollment of haemorrhage, gastrointestinal perforation, gastrointestinal or non-gastrointestinal fistula,
• •History of aneurism,
• •Hypokalemia, hypomagnesemia and hypocalcemia